Soligenix Inc —— 季度现金流量表 (NASDAQ:SNGX) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 8.97 M7.75 M5.76 M11.29 M9.24 M 负债总额 4.85 M4.13 M3.93 M3.7 M3.94 M 权益总额 4.12 M3.61 M1.83 M7.6 M5.29 M 负债及股东权益总额 8.97 M7.75 M5.76 M11.29 M9.24 M 总债务 111.86 K———— 净债务 111.86 K————

新闻

Soligenix旗下白塞病药物获英国监管机构认定

Soligenix receives UK regulatory designation for Behçet’s drug

Soligenix获欧洲药品管理局孤儿药资格积极意见

Soligenix receives positive EMA opinion for orphan drug status

Soligenix股票在贝赫切特病治疗数据积极后上涨

Soligenix stock rises after positive Behçet’s Disease treatment data

Soligenix公司SGX945治疗贝赫切特病的试验报告积极结果

Soligenix reports positive results from SGX945 trial for Behçet’s disease

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Soligenix (NASDAQ:SNGX)

Soligenix报告牛皮癣凝胶治疗试验取得积极结果

Soligenix reports positive results from psoriasis gel treatment trial

First patient dosed in Synairgen’s global phase 2 INVENT study